Talk:Ankylosing spondylitis

I have ankylosing spondylitis and have been put on Humira and methotrexate which has dramatically reduced my pain due to inflammation. I took every NSAID there is including Celebrex (Cox-2 drug). I didn’t see any mention of this newer medication. — Preceding unsigned comment added by 2601:5C6:C300:7A60:A421:15C9:A1BC:79C4 (talk) 21:36, 20 December 2020 (UTC)

"Combination of genetic and environmental factors"
ALL diseases known to man involve a combination of genetic and environmental factors, typically with one of those factors playing a greater role than the other. Why is this explanation being used so much these days in regard to diseases with unknown etiology? It does not aid in treatment, research or patient comfort. It essentially tells us nothing about the disease...other than that it is indeed a disease. Also, have any specific autoantibodies been shown to be strongly associated with ankylosing spondylitis? If not, then why is it being referred to as autoimmune. The autoimmune label is thrown around WAY too freely. Just because an inflammatory disease has an unknown (as of now) etiology, that doesn't make it autoimmune anymore than it makes it bacterial, viral or anything else. Cporosus1 (talk) 19:51, 5 December 2023 (UTC)


 * Maybe you should take up your issues with "genetic and environmental factors" with these guys, who happened to write a giant paper answering your questions, and still used that phrase. This took me all of 5 seconds to find in a search btw, maybe do some due diligence instead of ranting?
 * Basically, the exact etiology isn't known at this time, but it has extremely strong associations with HLA genes which encode for MHC proteins. Which implies that it is autoimmune. Feel free to read that link if you want a more detailed explanation. Just-a-can-of-beans (talk) 07:41, 12 February 2024 (UTC)

Treatment
"The Ministry of Health has registered the world's first drug for the treatment of Bekhterev's disease"

Quotes: "The drug is an effector antibody against a specific site of the TRBV9 T-cell receptor. This is the world's first therapeutic antibody binding to the TRBV9 segment".